Spots Global Cancer Trial Database for CellFX ® Percutaneous Electrode (PE) Treatment of Benign Thyroid Nodules

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: CellFX ® Percutaneous Electrode (PE) Treatment of Benign Thyroid Nodules

Official Title: First Clinical Feasibility Study Using the CellFX® Percutaneous Electrode (PE) System for the Treatment of Benign Thyroid Nodules

Study ID: NCT06117085

Conditions

Thyroid Nodule (Benign)

Interventions

CellFX® Percutaneous Electrode (PE) System

Study Description

Brief Summary: The objective of this clinical feasibility study is to evaluate initial clinical safety and device performance of the CellFX Percutaneous Electrode (PE) System for the treatment of symptomatic benign thyroid nodules.

Detailed Description: Cohort 1: (CellFX PE Procedure and Surgery) The first five enrolled subjects will be patients with planned thyroidectomy. The site investigator will perform the CellFX procedure followed by an ultrasound evaluation. The site investigator will then perform a partial or total thyroidectomy. Tissue samples from the CellFX targeted treated areas will be sent to the pathology lab for gross and histological evaluation. The participant will exit the study on the same day of surgery. Cohort 2: (CellFX PE Procedure with 12 months follow-up) When Cohort 1 is completed, up to 25 subjects will undergo a CellFX treatment using a percutaneous approach under ultrasound guidance. After CellFX treatment, all subjects will be followed weekly until 1 month, 3 months, 6 months and 12 months post-CellFX PE procedure.